|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/506 | (2006.01) |
| A61K 45/06 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 31/506 | (2013.01) | ||
| A61P 35/02 | (2006.01) | ||
| A61P 35/02 | (2018.01) |
| (11) | Patento numeris | 3600326 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 18718926.1 |
| Europos patento paraiškos padavimo data | 2018-03-29 | |
| (97) | Europos patento paraiškos paskelbimo data | 2020-02-05 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-01-25 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/IB2018/052187 |
| Data | 2018-03-29 |
| (87) | Numeris | WO 2018/178925 |
| Data | 2018-10-04 |
| (30) | Numeris | Data | Šalis |
| 201762479397 P | 2017-03-31 | US |
| (72) |
FERRETTI, Stephane , CH
GUERREIRO, Nelson , CH
JEAY, Sebastien , CH
JULLION, Astrid , CH
MEILLE, Christophe , CH
WUERTHNER, Jens , CH
FABRE, Claire , CH
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | DOSE AND REGIMEN FOR AN HDM2-P53 INTERACTION INHIBITOR IN HEMATOLOGICAL TUMORS |
| DOSE AND REGIMEN FOR AN HDM2-P53 INTERACTION INHIBITOR IN HEMATOLOGICAL TUMORS |